Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05424003 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 4, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Virginia Commonwealth University to University of Virginia
    • Primary and study completion dates: Feb 2026 to Aug 1, 2026
    v16
  2. Re-verified, no change to tracked fieldsv15
  3. Eligibility criteria expanded, about 6 wordsv14
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2024 to Feb 22, 2024
    • Site details revised
    v13
  5. Start date: Dec 2023 to Mar 2024v12
Show 10 earlier versionsHide 10 earlier versions
  1. Start date: Nov 2023 to Dec 2023v11
  2. Re-verified, no change to tracked fieldsv10
  3. Start date: Sep 2023 to Nov 2023v9
  4. Trial status: Suspended to Not Yet Recruiting
    • Start date: Jul 2023 to Sep 2023
    v8
  5. Trial status: Not Yet Recruiting to Suspended Sponsor's reason: Due to an international shortage of Semaglutide, this study has been put on hold until the study drug is available again.
    • Start date: Dec 2022 to Jul 2023
    v7
  6. Start date: Oct 2022 to Dec 2022v6
  7. Start date: Sep 2022 to Oct 2022v5
  8. Re-verified, no change to tracked fieldsv4
  9. Start date: Jul 2022 to Sep 2022v3
  10. Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 1 of 7 entries
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In this study, semaglutide will be compared to placebo (a look-alike inactive substance, a "sugar pill") to determine if its use will prevent weight gain after liver transplantation (LT). In addition, researchers will be testing to determine if semaglutide prevents the development of Non-Alcoholic Fatty Liver Disease (NAFLD) after transplant through Magnetic Resonance Imaging (MRI) and laboratory results.
Trial Details
NCT Number NCT05424003
Lead Sponsor University of Virginia
Collaborators: Novo Nordisk A/S
Conditions
(from sponsor)		 NAFLD
Related terms Non-alcoholic Fatty Liver Disease
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov